Initial strategies for integrating buprenorphine into HIV care settings in the United States

Lynn E. Sullivan, Robert D. Bruce, David Haltiwanger, Gregory M. Lucas, Lois Eldred, Ruth Finkelstein, David A. Fiellin

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


The Centers for Disease Control and Prevention's HIV Prevention Strategic Plan Through 2005 advocated for increasing the proportion of persons with human immunodeficiency virus (HIV) infection and in need of substance abuse treatment who are successfully linked to services for these 2 conditions. There is evidence that integrating care for HIV infection and substance abuse optimizes outcomes for patients with both disorders. Buprenorphine, a recently approved medication for the treatment of opioid dependence in physicians' offices, provides the opportunity to integrate the treatment of HIV infection and substance abuse in one clinical setting, yet little information exists on the models of care that will most successfully facilitate this integration. To promote the uptake of this type of integrated care, the current review provides a description of 4 recently implemented models for combining buprenorphine treatment with HIV primary care: (1) an on-site addiction/HIV specialist treatment model; (2) a HIV primary care physician model; (3) a nonphysician health professional model; and (4) a community outreach model.

Original languageEnglish (US)
Pages (from-to)S191-S196
JournalClinical Infectious Diseases
Issue numberSUPPL. 4
StatePublished - Dec 15 2006

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Initial strategies for integrating buprenorphine into HIV care settings in the United States'. Together they form a unique fingerprint.

Cite this